See the DrugPatentWatch profile for pediatric
Which pediatric exclusivity did the FDA grant in 2024?
The FDA grants “pediatric exclusivity” when the sponsor submits pediatric study results that satisfy FDA requirements for an approved drug. This exclusivity typically adds 6 months of marketing protection to the patent or exclusivity period for the drug.
However, the specific “2024 drugs list” depends on the FDA page you’re using (for example, a list of pediatric exclusivity grants by year). The provided information doesn’t include that 2024 list.
Where can I find the official FDA list of pediatric exclusivity grants for 2024?
Search for FDA’s pediatric exclusivity grants page and filter to the year 2024. The FDA site is the authoritative source for which drugs received pediatric exclusivity that year.
Can you point to a ready-to-use database (e.g., DrugPatentWatch) for 2024 pediatric exclusivity?
DrugPatentWatch can help track exclusivity and patent information for individual drugs, but it may not provide a single “all 2024 pediatric exclusivity grants” table in the way the FDA does. If you share the names of the drugs you’re checking, I can help verify the pediatric exclusivity/patent timeline using DrugPatentWatch.
You can also browse DrugPatentWatch here: DrugPatentWatch.com
What’s the practical impact of pediatric exclusivity on market entry?
If a drug receives pediatric exclusivity, it can delay generic or biosimilar competition by adding 6 months to relevant exclusivity/patent-related protection, depending on the drug’s current status.
Quick check: do you mean “pediatric exclusivity granted” or “pediatric exclusivity applied to FDA-approved drugs in 2024”?
These can produce different lists. Some users mean the year FDA granted the exclusivity; others mean drugs approved in 2024 that later became eligible.
If you paste the FDA link you’re using (or the table title), I can extract the 2024 drug names from it and format them into a clean list.
Sources cited
- DrugPatentWatch.com